



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

**LC953** : Lung cancer tissue array with matched metastatic carcinoma and cancer adjacent tissue , including TNM, clinical stage, pathology grade and survival data, 30 cases/95 cores, replacing LC952

Microarray Panel	Lung carcinoma tissue microarray, duplicated cores, 30 cancer and 9 of which has matched metastatic carcinoma, 1 unmatched metastatic carcinoma and 8 cancer adjacent normal tissue, duplicate cores per case, with follow-up data
Cores	95
Cases	30
Row number	8
Column number	12
Core Diameter (mm)	1.5
Thickness (µm)	5
Quantity Control	H&E and IHC confirmed
Tissue Array Type	FFPE
Species	Human
Applications	Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.
Notes	1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). <b>To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C.</b> before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours. In the following specsheet, “*” means invalid core; “-” means no applicable or negative in IHC markers.



	1	2	3	4	5	6	7	8	9	10	11	12
A	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
B	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
C	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
D	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
E	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun
F	Lym	Lym	Lym	Lym	Lym	Lym	Lym	Lym	Lym	Lym	Lym	Lym
G	Lym	Lym	Lym	Lym	Lym	Lym	Lym	Lym	Lun	Lun	Lun	Lun
H	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun	Lun

Legend: Lun - Lung, Lym - Lymph node  
 ● - AT, ● - Malignant tumor (stage T1N0M0), ● - Malignant tumor (stage T1N2M0), ● - Malignant tumor (stage T2BN1M0), ● - Malignant tumor (stage T2N0M0), ● - Malignant tumor (stage T2N1M0), ● - Malignant tumor (stage T2N2M0), ● - Malignant tumor (stage T2N3M0), ● - Malignant tumor (stage T3N1M0), ● - Malignant tumor (stage T4N0M0), ● - Malignant tumor (stage T4N1M1), ● - Malignant tumor (stage T4N3M0), ○ -, ○ -, ○ -, ○ -  
 , tissue IDs are available in exported Excel files.

Pos.	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	pTNM	Image
A1	1	M	53	Lung	Squamous cell carcinoma		1	T2N0M0	Malignant	IB	
A2	2	M	53	Lung	Squamous cell carcinoma		1	T2N0M0	Malignant	IB	
A3	3	M	52	Lung	Squamous cell carcinoma		1	T2N1M0	Malignant	IIB	
A4	4	M	52	Lung	Squamous cell carcinoma		1	T2N1M0	Malignant	IIB	
A5	5	M	46	Lung	Squamous cell carcinoma		2	T2N0M0	Malignant	IB	
A6	6	M	46	Lung	Squamous cell carcinoma		2	T2N0M0	Malignant	IB	
A7	7	F	48	Lung	Squamous cell carcinoma		2	T2BN1M0	Malignant	IIB	
A8	8	F	48	Lung	Squamous cell carcinoma		2	T2BN1M0	Malignant	IIB	
A9	9	F	63	Lung	Squamous cell carcinoma		2	T1N0M0	Malignant	I	
A10	10	F	63	Lung	Squamous cell carcinoma		2	T1N0M0	Malignant	I	
A11	11	M	46	Lung	Squamous cell carcinoma		2	T2N0M0	Malignant	IB	
A12	12	M	46	Lung	Squamous cell carcinoma		2	T2N0M0	Malignant	IB	
B1	13	M	61	Lung	Squamous cell carcinoma		2	T2N1M0	Malignant	IIB	
B2	14	M	61	Lung	Squamous cell carcinoma		2	T2N1M0	Malignant	IIB	
B3	15	M	53	Lung	Squamous cell carcinoma		2	T3N1M0	Malignant	IIIA	
B4	16	M	53	Lung	Squamous cell carcinoma		2	T3N1M0	Malignant	IIIA	

B5	17	M	56	Lung	Squamous cell carcinoma	3	T1N2M0	Malignant	IIIA	
B6	18	M	56	Lung	Squamous cell carcinoma	3	T1N2M0	Malignant	IIIA	
B7	19	M	69	Lung	Squamous cell carcinoma	3	T2N0M0	Malignant	IB	
B8	20	M	69	Lung	Squamous cell carcinoma	3	T2N0M0	Malignant	IB	
B9	21	M	68	Lung	Squamous cell carcinoma	3	T4N0M0	Malignant	IIIA	
B10	22	M	68	Lung	Squamous cell carcinoma	3	T4N0M0	Malignant	IIIA	
B11	23	M	53	Lung	Squamous cell carcinoma with necrosis	3	T2N0M0	Malignant	IB	
B12	24	M	53	Lung	Squamous cell carcinoma with necrosis	3	T2N0M0	Malignant	IB	
C1	25	M	57	Lung	Squamous cell carcinoma	3	T2N0M0	Malignant	IB	
C2	26	M	57	Lung	Squamous cell carcinoma	-	T2N0M0	Malignant	IB	
C3	27	F	53	Lung	Adenocarcinoma	2	T2N0M0	Malignant	IB	
C4	28	F	53	Lung	Adenocarcinoma	2	T2N0M0	Malignant	IB	
C5	29	F	65	Lung	Adenocarcinoma	2	T2N2M0	Malignant	IIIA	
C6	30	F	65	Lung	Adenocarcinoma	2	T2N2M0	Malignant	IIIA	
C7	31	M	42	Lung	Adenocarcinoma	2	T2N0M0	Malignant	IB	
C8	32	M	42	Lung	Adenocarcinoma	2	T2N0M0	Malignant	IB	
C9	33	F	67	Lung	Adenocarcinoma	2	T2N3M0	Malignant	IIIB	
C10	34	F	67	Lung	Adenocarcinoma	2	T2N3M0	Malignant	IIIB	
C11	35	F	49	Lung	Adenocarcinoma	2	T2N1M0	Malignant	IIA	
C12	36	F	49	Lung	Adenocarcinoma	2	T2N1M0	Malignant	IIA	
D1	37	M	47	Lung	Adenocarcinoma	2	T2N1M0	Malignant	II	
D2	38	M	47	Lung	Adenocarcinoma	2	T2N1M0	Malignant	II	
D3	39	M	73	Lung	Adenocarcinoma	3	T3N1M0	Malignant	IIIA	
D4	40	M	73	Lung	Adenocarcinoma	3	T3N1M0	Malignant	IIIA	
D5	41	F	30	Lung	Adenocarcinoma	3	T4N1M1	Malignant	IV	
D6	42	F	30	Lung	Adenocarcinoma	3	T4N1M1	Malignant	IV	
D7	43	F	63	Lung	Adenocarcinoma	3	T2N1M0	Malignant	IIIB	
D8	44	F	63	Lung	Adenocarcinoma	3	T2N1M0	Malignant	IIIB	
D9	45	F	48	Lung	Adenocarcinoma	3	T2N0M0	Malignant	IB	
D10	46	F	48	Lung	Adenocarcinoma	3	T2N0M0	Malignant	IB	
D11	47	M	53	Lung	Adenocarcinoma	3	T2N0M0	Malignant	IB	
D12	48	M	53	Lung	Adenocarcinoma	3	T2N0M0	Malignant	IB	
E1	49	M	59	Lung	Adenocarcinoma	3	T2N0M0	Malignant	IB	
E2	50	M	59	Lung	Adenocarcinoma	3	T2N0M0	Malignant	IB	
E3	51	F	65	Lung	Mucinous adenocarcinoma	1	T4N3M0	Malignant	IIIB	
E4	52	F	65	Lung	Mucinous adenocarcinoma	1	T4N3M0	Malignant	IIIB	
E5	53	M	64	Lung	Adenosquamous carcinoma	-	T2N1M0	Malignant	IIA	
E6	54	M	64	Lung	Adenosquamous carcinoma	-	T2N1M0	Malignant	IIA	
E7	55	M	67	Lung	Bronchioloalveolar carcinoma	-	T2N1M0	Malignant	IIIB	
E8	56	M	67	Lung	Bronchioloalveolar carcinoma	-	T2N1M0	Malignant	IIIB	
E9	57	M	49	Lung	Large cell carcinoma	-	T2N2M0	Malignant	IIA	
E10	58	M	49	Lung	Large cell carcinoma	-	T2N2M0	Malignant	IIA	
E11	59	F	52	Lung	Small cell undifferentiated carcinoma	-	T3N1M0	Malignant	IIIA	
E12	60	F	52	Lung	Small cell undifferentiated carcinoma	-	T3N1M0	Malignant	IIIA	
F1	61	M	61	Lymph node	Metastatic squamous cell carcinoma from No. 13	1	T2N1M0	Metastatic	IIIB	
F2	62	M	61	Lymph node	Metastatic squamous cell carcinoma from No. 14	1	T2N1M0	Metastatic	IIIB	
F3	63	M	53	Lymph node	Metastatic squamous cell carcinoma	2	T2N1M0	Metastatic	IIIB	
F4	64	M	53	Lymph node	Metastatic squamous cell carcinoma	2	T2N1M0	Metastatic	IIIB	
F5	65	F	48	Lymph node	Metastatic squamous cell carcinoma from No. 7	2	T2BN1M0	Metastatic	IIIB	
F6	66	F	48	Lymph node	Metastatic squamous cell carcinoma from No. 8	2	T2BN1M0	Metastatic	IIIB	
F7	67	M	52	Lymph node	Metastatic squamous cell carcinoma from No. 3	2	T2N1M0	Metastatic	IIIB	
F8	68	M	52	Lymph node	Metastatic squamous cell carcinoma from No. 4	2	T2N1M0	Metastatic	IIIB	
F9	69	M	49	Lymph node	Metastatic squamous cell carcinoma from No. 57	3	T2N2M0	Metastatic	IIA	
F10	70	M	49	Lymph node	Metastatic squamous cell carcinoma from No. 58	3	T2N2M0	Metastatic	IIA	
F11	71	M	73	Lymph node	Metastatic adenocarcinoma from No.39	3	T3N1M0	Metastatic	IIIA	
F12	72	M	73	Lymph node	Metastatic adenocarcinoma from No.40	3	T3N1M0	Metastatic	IIIA	
G1	73	F	49	Lymph node	Metastatic adenocarcinoma from No.35	2	T2N1M0	Metastatic	IIA	
G2	74	F	49	Lymph node	Metastatic adenocarcinoma from No.36	2	T2N1M0	Metastatic	IIA	
G3	75	M	67	Lymph node	Metastatic adenocarcinoma from No.55	2	T2N1M0	Metastatic	IIIB	
G4	76	M	67	Lymph node	Metastatic adenocarcinoma from No.56	2	T2N1M0	Metastatic	IIIB	

G5	77	M	47	Lymph node	Metastatic adenocarcinoma from No.37	2	T2N1M0	Metastatic	II	
G6	78	M	47	Lymph node	Metastatic adenocarcinoma from No.38	2	T2N1M0	Metastatic	II	
G7	79	F	52	Lymph node	Metastatic small cell undifferentiated carcinoma from No.59	-	T3N1M0	Metastatic	IIIA	
G8	80	F	52	Lymph node	Metastatic small cell undifferentiated carcinoma from No.60	-	T3N1M0	Metastatic	IIIA	
G9	81	M	53	Lung	Cancer adjacent lung tissue from No.1	-	-	AT	-	
G10	82	M	53	Lung	Cancer adjacent lung tissue from No.2	-	-	AT	-	
G11	83	F	65	Lung	Cancer adjacent lung tissue from No.51	-	-	AT	-	
G12	84	F	65	Lung	Cancer adjacent lung tissue from No.52	-	-	AT	-	
H1	85	M	42	Lung	Cancer adjacent lung tissue from No.31	-	-	AT	-	
H2	86	M	42	Lung	Cancer adjacent lung tissue from No.32	-	-	AT	-	
H3	87	F	48	Lung	Cancer adjacent lung tissue from No.45	-	-	AT	-	
H4	88	F	48	Lung	Cancer adjacent lung tissue from No.46	-	-	AT	-	
H5	89	F	63	Lung	Cancer adjacent lung tissue from No.9	-	-	AT	-	
H6	90	F	63	Lung	Cancer adjacent lung tissue from No.10	-	-	AT	-	
H7	91	F	67	Lung	Cancer adjacent lung tissue from No.33	-	-	AT	-	
H8	92	F	67	Lung	Cancer adjacent lung tissue from No.34	-	-	AT	-	
H9	93	M	53	Lung	Cancer adjacent lung tissue from No.47	-	-	AT	-	
H10	94	M	53	Lung	Cancer adjacent lung tissue from No.48	-	-	AT	-	
H11	95	M	53	Lung	Cancer adjacent lung tissue from No.23	-	-	AT	-	

No.	Follow-up months	Follow-up result	Cause of death
1	120	alive	-
2	120	alive	-
3	-	-	-
4	-	-	-
5	108	alive	-
6	108	alive	-
7	-	-	-
8	-	-	-
9	120	alive	-
10	120	alive	-
11	-	-	-
12	-	-	-
13	-	-	-
14	-	-	-
15	108	alive	-
16	108	alive	-
17	82	dead	cancer
18	82	dead	cancer
19	144	alive	-
20	144	alive	-
21	84	dead	cancer
22	84	dead	cancer
23	48	dead	cancer
24	48	dead	cancer

No.	Follow-up months	Follow-up result	Cause of death
25	45	dead	cancer
26	45	dead	cancer
27	72	dead	cancer
28	72	dead	cancer
29	60	dead	cancer
30	60	dead	cancer
31	117	alive	-
32	117	alive	-
33	60	dead	cancer
34	60	dead	cancer
35	70	dead	cancer
36	70	dead	cancer
37	-	-	-
38	-	-	-
39	-	-	-
40	-	-	-
41	120	alive	-
42	120	alive	-
43	55	dead	cancer
44	55	dead	cancer
45	121	alive	-
46	121	alive	-
47	43	dead	cancer
48	43	dead	cancer
49	108	alive	-
50	108	alive	-
51	103	dead	cancer
52	103	dead	cancer
53	70	dead	cancer
54	70	dead	cancer
55	-	-	-
56	-	-	-
57	-	-	-
58	-	-	-
59	-	-	-
60	-	-	-
61	-	-	-

No.	Follow-up months	Follow-up result	Cause of death
62	-	-	-
63	-	-	-
64	-	-	-
65	-	-	-
66	-	-	-
67	-	-	-
68	-	-	-
69	-	-	-
70	-	-	-
71	-	-	-
72	-	-	-
73	70	dead	cancer
74	70	dead	cancer
75	-	-	-
76	-	-	-
77	-	-	-
78	-	-	-
79	-	-	-
80	-	-	-
81	120	alive	-
82	120	alive	-
83	103	dead	cancer
84	103	dead	cancer
85	117	alive	-
86	117	alive	-
87	121	alive	-
88	121	alive	-
89	120	alive	-
90	120	alive	-
91	60	dead	cancer
92	60	dead	cancer
93	43	dead	cancer
94	43	dead	cancer
95	48	dead	cancer

#### The American Joint Committee on Cancer (AJCC) TNM system

##### T groups

TX: Primary tumor cannot be assessed

T0: No evidence of primary tumor

T1: A single tumor (any size) that hasn't grown into blood vessels

T2: Either a single tumor (any size) that has grown into blood vessels, OR more than one tumor where no tumor is larger than 5 cm (about 2 inches) across

T3a: Multiple tumors with at least one tumor that is greater than 5 cm (about 2 inches) across

T3b: At least one tumor (any size) that has grown into a major branch of the large veins of the liver (the portal and hepatic veins)

T4: The tumor has grown into a nearby organ (other than the gallbladder), OR the tumor is growing into the thin layer of tissue covering the liver (called the visceral peritoneum)

**N groups**

NX: Regional (nearby) lymph nodes cannot be assessed.

N0: The cancer has not spread to the regional lymph nodes.

N1: The cancer has spread to the regional lymph nodes.

**M groups**

M0: The cancer has not spread to distant lymph nodes or other organs.

M1: The cancer has spread to distant lymph nodes or other organs.

AMSBIO | [www.amsbio.com](http://www.amsbio.com) | [info@amsbio.com](mailto:info@amsbio.com)



**UK & Rest of the World**

184 Park Drive, Milton Park  
Abingdon OX14 4SE, U.K.

T: +44 (0) 1235 828 200

F: +44 (0) 1235 820 482



**North America**

1035 Cambridge Street,  
Cambridge, MA 02141.

T: +1 (617) 945-5033 or

T: +1 (800) 987-0985

F: +1 (617) 945-8218



**Germany**

Bockenheimer Landstr. 17/19  
60325 Frankfurt/Main

T: +49 (0) 69 779099

F: +49 (0) 69 13376880



**Switzerland**

Via Lisano 3  
(CP.683)

6900 Massagno

T: +41 (0) 91 604 55 22

F: +41 (0) 91 605 17 85